THALES
8.6.2021 09:02:12 CEST | Business Wire | Press release
The award winning* Cinterion® IoT Suite Connectivity Activation by Thales greatly simplifies and digitalises cellular connectivity and the daily operations of industrial IoT device manufacturers and service providers. Based on standard eSIM technology, the new solution eliminates the need for IoT service providers to setup and run complex eSIM Remote Subscription Provisioning (RSP) platforms. It uses a single IoT eSIM that works with whichever mobile operator is selected by the device manufacturer or IoT service provider. The solution also enables resilient device connectivity and lifecycle management over the multi-year life spans of industrial solutions thereby delivering a reduction in Total Cost of Ownership for customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005041/en/
By 2025, 75 billion IoT devices will be connected with a potential market value of around $1.6 trillion. This not only brings unprecedented business opportunities, but also challenges such as how to streamline supply chain logistics for smart devices.
The solution simplifies manufacturing processes and logistics : In fact, device manufacturers no longer need to produce multiple product variants for deployment with different Mobile Network Operators (MNOs) in different countries. One product now fits all MNO networks as the IoT eSIM embedded in the industrial device can connect to any MNO network worldwide.
Thales system shortens device installation: Thanks to a remote activation process, the IoT eSIM automatically downloads the MNO profile that best suits the device location and connects to the network according to the service providers’ pre-defined business rules.
The solution guarantees network resilience and longevity : As networks and IoT applications evolve, the solution ensures reliable connectivity and business continuity by automatically switching to back-up connectivity providers removing the need for physical device updates.
“Thales leverages its unique expertise of cellular network infrastructure and collaboration with more than 400 mobile operators to simplify industrial IoT connectivity.The Thales Connectivity solution offers all the benefits of digitalisation and eSIM technology for the industrial IoT sector. With more than 25 years of constant innovation in IoT connectivity solutions, Thales enables the best total-cost-of-ownership and performance to its customers.” Frederic Deman, SVP of Analytics and IoT Solutions Business Line, at Thales.
“The IoT eSIM solution is a huge step forward for Aidon helping to ensure production flexibility and connectivity of our smart meters, even in rural areas, and all without the need for physical handling of SIMs,” said Petri Ounila, Director, IoT Devices, Aidon. “The solution co-developed with Thales provides a true operator selection and provisioning at any stage of the product lifetime. It is improving our ability to get smart meters connected, stay connected and adapt to new metering as-a-service business models.”
“The Thales Cinterion Connectivity Activation solution turns traditional methods of IoT device service provisioning and updating on its head, bringing new levels of service digitization, automation, Over-the-Air (OTA) management, and digital security to industrial IoT solutions” said Phil Sealy, Research Director at ABI Research . “Device manufacturers and service providers will no longer be tied to complex connectivity device design and logistics, thanks to a simplified and flexible approach. By easing the path to cellular connectivity and management, device manufacturers and service providers can redshift their focus toward innovation and scaling digital transformation for their customers.”
To learn more, join one of our virtual launch events on June 16 at 9:00 AM or 5:00 PM CEST.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
Thales Group
Digital Identity & Security page
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005041/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom